SUSPECT ADVERSE REACTION REPORT

PA-TOLMAR, INC.-25PA057005

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE Years	3. SEX	4-6 REACTION ONSET		
		Day	Month	Year			Day	Month	Year
F-J	PANAMA	09	Dec	1939	85	Male	21	Aug	2025

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data)

1) HE HAS DETERIORATED IN A FEW WEEKS/IMPAIRMENT (General physical health deterioration (10049438), General physical health deterioration (10049438))
Recovering/Resolving
2) BEDRIDDEN (Bedridden (10048948), Bedridden (10048948))
Not Recovered/Not Resolved/Ongoing
3) Pneumonia (Pneumonia (10035664), Pneumonia (10035664))
(21/Aug/2025 -) - Not Recovered/Not Resolved/Ongoing

Cont..

8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION

- ☐ PATIENT DIED
- ☐ LIFE THREATENING
- ☑ INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION
- ☐ RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY
- ☐ CONGENITAL ANOMALY
- ☑ OTHER MEDICALLY IMPORTANT CONDITION

II. SUSPECT DRUG(S)INFORMATION

14. SUSPECT DRUG(S)(include generic name)

1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (Injection)(15276CUY; Unk; Unk)

Cont..

15. DAILY DOSE(S)

1) (45 milligram(s), 1 in 6 Month)

Cont..

16. ROUTE(S) OF ADMINISTRATION

1) Subcutaneous

Cont..

17. INDICATION(S) FOR USE

1) Prostate cancer [10060862 - Prostate cancer]

Cont..

18. THERAPY DATE(S) (from/to)

1) (01/Dec/2023 - Ongoing)

19. THERAPY DURATION

20. DID EVENT ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☑ NA

21. DID EVENT REAPPEAR AFTER REINTRODUCTION ☐ YES ☐ NO ☑ NA

(NA : Not Applicable)

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

No concomitants used/reported

23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

1) PROSTATE CANCER (10060862, Prostate cancer) (Continuing: Yes)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER

Name : Tolmar, Inc
701 Centre Avenue
Fort Collins, CO, 80526, UNITED STATES OF AMERICA
Anjan.Chatterjee@tolmar.comand+1-9702124900

Study Information
Study Name: NA
EudraCT Number:
Protocol No.: NA
Center No.:
Subject Id :

24.REPORT NULLIFIED ☐ YES ☐ NO

24b. MFR CONTROL NO.

PA-TOLMAR, INC.-25PA057005

24c. DATE RECEIVED BY MANUFACTURER

26/Aug/2025

24d. REPORT SOURCE ☑ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL

DATE OF THIS REPORT

28/Aug/2025

25a. REPORT TYPE ☐ INITIAL ☑ FOLLOWUP

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

4) ULCER ON THE SACRUM/sacral ulcer (Decubitus ulcer (10011985), Decubitus ulcer (10011985) - Recovering/Resolving)

5) ULCER ON THE RIGHT THIGH (Skin ulcer (10040943), Skin ulcer (10040943) - Recovering/Resolving)

Event Description :

This Study report from PANAMA was received by Adium via Patient Support Program (reference number: PA-ADIUM-PA-0009-20250219) on 19-FEB-2025 from a Consumer/Other Non-Health Prof regarding an Elderly 85 Years old Male patient who experienced non serious events of he has deteriorated in a few weeks (General physical health deterioration), Ulcer on the sacrum (Decubitus ulcer), Ulcer on the right thigh (Skin ulcer) during Eligard (Leuprolide acetate) 45 milligram therapy for Prostate cancer. The needle component of the constituent device was not identified in the report. Xtandi (enzalutamide) was also considered as suspect. The report was sent to Tolmar on 20-FEB-2025.

The patient's medical history and current conditions included Prostate cancer.

Concomitant medications were not reported.

On 01-DEC-2023, the patient began receiving Eligard 45 milligram, q 6 month via Subcutaneous use for Prostate cancer (Lot numbers: unknown; Expiration date: unknown). On the same day, the patient began receiving Xtandi 160 milligram, qd, via oral route for Prostate cancer (Lot numbers: unknown; Expiration date: unknown).

On an unspecified date, after an unspecified amount of time from last dose of Eligard, the patient was bedridden with caregiver at home as all the care needed to be performed at bed. Since an unspecified date, patient had two ulcers, one on the sacrum and the other on the right thigh. The patient had deteriorated in a few weeks.

Corrective treatment was not reported.

Action taken with Eligard in response to the events was Dose Not Changed. De-challenge and re-challenge were not applicable.

The outcome of General physical health deterioration was Not Recovered. The outcome of Decubitus ulcer and skin ulcer was unknown.

The reporter did not assess the seriousness and causality of the events in relationship to Eligard and Eligard unspecified device.

On 18-MAR-2025, follow-up information was received by Adium PSP - Prevenfuturo (reference number: PA-ADIUM-PA-0009-20250219) from Consumer/Other Non-Health Prof and sent to Tolmar on 19-MAR-2025. New information included: Upgraded the case to serious. Added new serious (medically significant) event of Bedridden (Bedridden).

On an unspecified date, unknown time after most recent dose of Eligard, the patient was bedridden with caregiver at home as all the care needed to be performed at bed.

Corrective treatment was not reported.

Action taken with Eligard in response to the events was Dose Not Changed. De-challenge and re-challenge were not applicable.

The outcome of Bedridden was Not Recovered.

The reporter did not assess the seriousness and causality of the events in relationship to Eligard and Eligard unspecified device.

On 24-Apr-2025, the follow up information was received via Adium (reference number: PA-ADIUM-PA-0009-2025021) from a consumer (consumer or non-healthcare professional) and sent to Tolmar on 25-Apr-2025. New information included: Batch lot number and expiration date of Eligard. Verbatim updated from “ULCER ON THE SACRUM” to “ULCER ON THE SACRUM/sacral ulcer” (decubitus ulcer) along with the outcome from “unknown” to “recovering”. Verbatim updated from "HE HAS DETERIORATED IN A FEW WEEKS" to "HE HAS DETERIORATED IN A FEW WEEKS/ IMPAIRMENT" (General physical health deterioration) along with the outcome from "not recovered" to "recovering". Outcome of the event “ULCER ON THE RIGHT THIGH” (skin ulcer) updated from “unknown” to “recovering”. Updated seriousness of the event of General physical health deterioration from non-serious to serious due to hospitalization.

On an unknown date, patient had ulcer on right thigh and sacral ulcer. Patient had impairment in a few weeks for which he was hospitalized. No further information available.

Corrective treatment was unknown.

Action taken with Eligard in response to the events was dose not changed. De-challenge and re-challenge were not applicable.

The outcome of decubitus ulcer, skin ulcer and General physical health deterioration was recovering.

The reporter did not assess the seriousness of decubitus ulcer, skin ulcer.

Continuation Sheet for CIOMS report

The reporter assessed the seriousness of General physical health deterioration as serious (hospitalization).

The reporter did not assess the causality of decubitus ulcer, skin ulcer and General physical health deterioration in relationship to Eligard and Eligard unspecified device.

No follow up queries were raised.

On 26-Aug-2025, follow up information was received by Adium via "ASOFARMA A TU LADO" Patient Support Program (reference number: PA-ADIUM-PA-0009-20250219 (3)) from a consumer (non-healthcare professional) and sent to Tolmar on 27-Aug-2025. New information included: Added a new serious (hospitalization) event of "Pneumonia" (Pneumonia).

On 21-Aug-2025, the patient was hospitalised due to pneumonia. No further information was available.

No further corrective treatment was provided.

Action taken with Eligard in response to the event was dose not changed. Dechallenge and rechallenge were not applicable.

The outcome of pneumonia was not recovered.

The reporter assessed the seriousness of pneumonia as serious (hospitalization).

The reporter assessed the causality of pneumonia in relationship to Eligard and Eligard unspecified device as related.

No further information is expected as consent to be contacted was not provided.

Listedness of events general physical health deterioration, bedridden, decubitus ulcer and skin ulcer were retained as per previous assessment.

Pneumonia >Eligard® >unlisted as per CCDS Eligard®> 7-Nov-2024
Pneumonia> Eligard® >unlisted as per Canadian Monograph Eligard®> 2-Apr-2025
Pneumonia> Eligard®>unlisted as per USPI Eligard®>Feb-2025
Pneumonia> Eligard® Unspecified Device>unlisted as per USPI Eligard®>Feb-2025

Company Remarks (Sender's Comments) :

Evaluator comment (Tolmar): This is regarding an elderly 85-year-old male patient who experienced general physical health deterioration (he has deteriorated in a few weeks), decubitus ulcer (Ulcer on the sacrum), skin ulcer (Ulcer on the right thigh) and patient is bedridden (bedridden) during Eligard (Leuprolide acetate) 45 mg therapy for prostate cancer. Xtandi (enzalutamide) was also considered as suspect. Tolmar assessed the events general physical health deterioration (hospitalisation and MS) and bedridden as serious (MS) based on the clinical relevance of the events and their significant impact on patient's health, while decubitus ulcer and skin ulcer are considered as non-serious as they did not meet ICH seriousness criteria. All the events are considered as not related to Eligard (drug and device) based on the etiopathogenesis of the events reported and their inconsistency with the product safety profile. Elderly age and underlying prostate cancer are considered as strong risk factors.

FU added event pneumonia(pneumonia). Tolmar assessed the event pneumonia as serious as it resulted in hospitalisation. The causality of event pneumonia was assessed as not related to suspect Eligard(drug and device) considering the clinical nature of event, pneumonia being infective in nature and Eligard is not known to cause infections. Elderly age and immunocompromised state due to underlying prostate cancer can increase the risk factor in patient and make them more susceptible to infections.

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug	: Eligard® (Leuprolide acetate)
Active Substance	: 1) Leuprolide acetate
Drug Characterization	: Suspect
Form of Admin	: 1) Injection
Lot Number	: 1) 15276CUY; Unk; Unk
Daily Dose	: (45 milligram(s), 1 in 6 Month)
Route of Admin	: 1) Subcutaneous
Indications	: 1) Prostate cancer [10060862 - Prostate cancer]
Therapy Dates	: 1) From : 01/Dec/2023 To :Continuing
Action(s) Taken With Drug	: Dose not changed

Causality

1) HE HAS DETERIORATED IN A FEW WEEKS/IMPAIRMENT (General physical health deterioration - 10049438, General physical health deterioration - 10049438)

Causality as per reporter	: Not Reported

Continuation Sheet for CIOMS report

Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

2) BEDRIDDEN (Bedridden - 10048948, Bedridden - 10048948)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

3) Pneumonia (Pneumonia - 10035664, Pneumonia - 10035664)
Causality as per reporter : Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

4) ULCER ON THE SACRUM/sacral ulcer (Decubitus ulcer - 10011985, Decubitus ulcer - 10011985)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

5) ULCER ON THE RIGHT THIGH (Skin ulcer - 10040943, Skin ulcer - 10040943)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) HE HAS DETERIORATED IN A FEW WEEKS/IMPAIRMENT
CORE UnLabeled
2) BEDRIDDEN
CORE UnLabeled
3) Pneumonia
CORE UnLabeled
4) ULCER ON THE SACRUM/sacral ulcer
CORE UnLabeled
5) ULCER ON THE RIGHT THIGH
CORE UnLabeled

2) Drug : Eligard® Unspecified Device (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form of Admin : 1) Injection
Lot Number : 1) 15276CUY; Unk; Unk
Indications : 1) Prostate cancer [10060862 - Prostate cancer]
Action(s) Taken With Drug : Not applicable

Causality

1) HE HAS DETERIORATED IN A FEW WEEKS/IMPAIRMENT (General physical health deterioration - 10049438, General physical health deterioration - 10049438)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

2) BEDRIDDEN (Bedridden - 10048948, Bedridden - 10048948)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

3) Pneumonia (Pneumonia - 10035664, Pneumonia - 10035664)
Causality as per reporter : Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

4) ULCER ON THE SACRUM/sacral ulcer (Decubitus ulcer - 10011985, Decubitus ulcer - 10011985)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

5) ULCER ON THE RIGHT THIGH (Skin ulcer - 10040943, Skin ulcer - 10040943)

Continuation Sheet for CIOMS report

Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) HE HAS DETERIORATED IN A FEW WEEKS/IMPAIRMENT
CORE
2) BEDRIDDEN
CORE
3) Pneumonia
CORE
4) ULCER ON THE SACRUM/sacral ulcer
CORE
5) ULCER ON THE RIGHT THIGH
CORE

3) Drug : XTANDI
Active Substance : 1) ENZALUTAMIDE
Drug Characterization : Suspect
Form of Admin : 1) Capsule
Lot Number : 1) Unknown
Daily Dose : (40 milligram(s), 4 in 1 Day)
Route of Admin : 1) Oral
Indications : 1) Prostate cancer [10060862 - Prostate cancer]
Therapy Dates : 1) From : 01/Dec/2023 To :Continuing
Action(s) Taken With Drug : Dose not changed

Causality

1) HE HAS DETERIORATED IN A FEW WEEKS/IMPAIRMENT (General physical health deterioration - 10049438, General physical health deterioration - 10049438)
Causality as per reporter : Not Reported
Causality as per Mfr : Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

2) BEDRIDDEN (Bedridden - 10048948, Bedridden - 10048948)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

3) Pneumonia (Pneumonia - 10035664, Pneumonia - 10035664)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

4) ULCER ON THE SACRUM/sacral ulcer (Decubitus ulcer - 10011985, Decubitus ulcer - 10011985)
Causality as per reporter : Not Reported
Causality as per Mfr : Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

5) ULCER ON THE RIGHT THIGH (Skin ulcer - 10040943, Skin ulcer - 10040943)
Causality as per reporter : Not Reported
Causality as per Mfr : Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

15. DAILY DOSE(S) (Continuation...)

Dosage Text :

Drug 1 :Eligard®

1) 45 milligram, q 6 month